Mandel Center for Heart and Vascular Research, and the Duke Cardiovascular Research Center, Duke University Medical Center, CaRL Building, 213 Research Drive, Durham, NC, 27710, USA.
Sci Rep. 2023 Mar 9;13(1):3920. doi: 10.1038/s41598-023-31144-3.
Current methods to generate cardiomyocytes from induced pluripotent stem cells (iPSc) utilize broad-spectrum pharmacological inhibitors. These methods give rise to cardiomyocytes which are typically immature. Since we have recently demonstrated that cardiomyogenesis in vitro and in vivo requires Sfrp2, we asked if Sfrp2 would drive differentiation of human iPSc into cardiomyocytes. Indeed, we found that Sfrp2 induced robust cardiac differentiation. Importantly, replacement of broad spectrum pharmacological inhibitors with Sfrp2 gave rise to mature cardiomyocytes as evidenced by their sarcomere structure, electrophysiological profiles, and ability to form gap junctions.
目前，从诱导多能干细胞（iPSC）生成心肌细胞的方法使用了广谱的药理学抑制剂。这些方法产生的心肌细胞通常是不成熟的。由于我们最近证明了体外和体内的心肌发生需要 Sfrp2，我们就想知道 Sfrp2 是否会促使人类 iPSC 分化为心肌细胞。事实上，我们发现 Sfrp2 能强烈诱导心脏分化。重要的是，用 Sfrp2 替代广谱的药理学抑制剂会产生成熟的心肌细胞，这可以从它们的肌节结构、电生理特征和形成间隙连接的能力得到证明。
